CLSD · As filed with the SEC
Clearside Biomedical cash flow statement, by quarter
The statement as Clearside Biomedical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows (unaudited) · USD
| USD | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 | Q1 2024 3 months ended Mar 31, 2024 | Q4 2023 3 months ended Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||
| Net loss | — | — | (8,223,000) | — | — | — | (11,763,000) | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Non-cash interest expense on liability related to the sales of future royalties, net of issuance costs accretion | — | — | 2,673,000 | — | — | — | 2,403,000 | — |
| Depreciation | — | — | 85,000 | — | — | — | 28,000 | — |
| Share-based compensation expense | — | — | 721,000 | — | — | — | 1,062,000 | — |
| Change in fair value of warrant liabilities | — | — | (207,000) | — | — | — | 712,000 | — |
| Issuance costs allocated to warrant liabilities | — | — | 0 | — | — | — | 787,000 | — |
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | — | — | (1,082,000) | — | — | — | 443,000 | — |
| Other assets and liabilities | — | — | (12,000) | — | — | — | (488,000) | — |
| Accounts payable and accrued liabilities (includes $223 to a related party for the nine months ended September 30, 2024) | — | — | 215,000 | — | — | — | (1,110,000) | — |
| Deferred revenue | — | — | 0 | — | — | — | 75,000 | — |
| Net cash used in operating activities | — | — | (5,830,000) | — | — | — | (7,851,000) | — |
| Investing activities | ||||||||
| Acquisition of property and equipment | — | — | (9,000) | — | — | — | (57,000) | — |
| Net cash used in investing activities | — | — | (9,000) | — | — | — | (57,000) | — |
| Financing activities | ||||||||
| Proceeds from issuance of common stock and warrants under registered direct offering, net of issuance costs | — | — | 0 | — | — | — | 13,860,000 | — |
| Proceeds from at-the-market sales agreement, net of issuance costs | — | — | 434,000 | — | — | — | 450,000 | — |
| Payments on royalty purchase and sale agreement | — | — | (1,000,000) | — | — | — | — | — |
| Proceeds from exercise of stock options | — | — | 0 | — | — | — | 12,000 | — |
| Proceeds from shares issued under employee stock purchase plan | — | — | 13,000 | — | — | — | 21,000 | — |
| Net cash provided by financing activities | — | — | (553,000) | — | — | — | 14,343,000 | — |
| Net decrease in cash and cash equivalents | — | — | (6,392,000) | — | — | — | 6,435,000 | — |
| Cash and cash equivalents, beginning of period | 9,376,000 | 13,628,000 | 20,020,000 | 13,888,000 | 18,238,000 | 35,355,000 | 28,920,000 | 28,802,000 |
| Cash and cash equivalent, end of period | 6,801,000 | 9,376,000 | 13,628,000 | 20,020,000 | 13,888,000 | 18,238,000 | 35,355,000 | 28,920,000 |
| Supplemental disclosure | ||||||||
| Purchase of property and equipment included in accrued liabilities | — | — | 0 | — | — | — | 163,000 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.